주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기
통합검색
로그인
고객센터
주요메뉴
질환포커스
세계의약뉴스
국내의약뉴스
성상변경내역
약제급여기준 개정내역
제약업계 소식
메디컬포커스
컨퍼런스
CME
근골격계
남성건강
내분비대사계
면역계
비뇨기계
뇌심혈관계
종양
호흡기계
감각기관계
중추신경계
소화기계
감염계
혈액 및 조혈계
미용
기타
최근 해외학술대회의 주요 발표내용을 제공합니다.
컨퍼런스 커버리지
2024 San Antonio Breast Cancer Symposium (SABCS 2024)
10 Dec - 12 Dec, 2024, United States OLD
Active monitoring safe for low-risk ductal carcinoma in situ
2025-02-21
Among women with low-risk ductal carcinoma in situ, the incidence of invasive cancer in the same breast does not appear to be different between those who have undergone active monitoring and those who have received a surgical procedure, according to the results of COMET trial.
Add-on palbociclib may overcome resistance to anti-HER2 Tx, ET in HR+, HER2+ mBC
2025-02-21
The addition of the CDK4/6 inhibitor palbociclib to anti-HER2 and endocrine therapy (ET) significantly improves progression-free survival (PFS) in patients with hormone receptor-positive, HER-positive (HR+, HER+) metastatic breast cancer (mBC) in the first-line setting, according to the results of the phase III AFT-38 PATINA trial.
Ipsilateral breast cancer recurrence in ‘good-risk’ DCIS reduced with tamoxifen
2025-02-21
Adjuvant use of tamoxifen is associated with a big drop in the risk of recurrence in the same breast among patients with “good-risk” ductal carcinoma in situ (DCIS) after breast-conserving surgery without radiotherapy.
Palbociclib plus endocrine therapy prolongs TTF, survival in metastatic breast cancer
2025-02-21
First-line endocrine therapy (ET) plus palbociclib (palb/ET) performs better than mono-chemotherapy in improving time to treatment failure (TTF) and progression-free survival (PFS) in women with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC), as shown by the results of the phase III PADMA trial.
Recurrence scores from 21-gene assay help inform benefits of adjuvant anthracyclines in EBC
2025-02-21
The recurrence score derived from a 21-gene expression assay may indicate which patients with early-stage HR+ breast cancer can maintain freedom from distant recurrence for longer with the inclusion of an anthracycline in adjuvant chemotherapy, suggests a post hoc analysis of the TAILORx trial presented at SABCS 2024
Risk-reducing surgeries tied to improved outcomes in BRCA carriers with young-onset BC
2025-02-21
A large global study provides evidence that risk-reducing mastectomy (RRM) and/or risk-reducing salpingo-oophorectomy (RRSO) is associated with improved survival outcomes in young women diagnosed with breast cancer (BC) at or before 40 years of age who were harbouring germline BRCA1 and/or BRCA2 pathogenic variants (PVs).
Trastuzumab deruxtecan improves PFS in metastatic breast cancer with rapid progression
2025-02-21
Treatment with trastuzumab deruxtecan (T-DXd) results in longer progression-free survival (PFS) in patients with hormone receptor?positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC) compared with physician’s choice of chemotherapy, according to the results of the phase III DESTINY-Breast06 study presented at SABCS 2024. In addition, no new safety signals have been identified.
1
최근 본 콘텐츠
최근 본 콘텐츠가 없습니다
관심제품
관심콘텐츠
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
